RFL (Rafael Holdings) Quality Rank


RFL Rafael Holdings Inc RFL
48 GF Score
Price $2.23
GF Value $1.36
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Rafael Holdings Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Rafael Holdings Quality Rank Related Terms

RFL
48GF Score
Rafael Holdings Inc RFL
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Rafael Holdings (RFL) Overvalued in 2026?

Based on GuruFocus' analysis, Rafael Holdings stock appears to be overvalued. The current stock price of $2.23 is trading 64% above its estimated GF Value™ of $1.36. GuruFocus considers Rafael Holdings to be Significantly Overvalued.

Key valuation signals for RFL:

  • Quality Rank:
  • GF Value™: $1.36 vs. price of $2.23 (64% above fair value)
  • GF Score™: 48/100 with 5 warning signs

No single metric tells the full story. See the RFL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rafael Holdings Business Description

Address 520 Broad Street, Newark, NJ, USA, 07102
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
48GF Score

Get the complete analysis for RFL

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.23
Price
$1.36
GF Value